Who
Laurie Keating
Director
Company insider
Files Form 4 as: Director, Kalaris Therapeutics; Director, PepGen; Director, Immuneering; Director, Imago BioSciences; EVP, Chief Legal Officer, Alnylam Pharmaceuticals.
In numbers
- Trades disclosed
- 155
- Buys
- 4
- Sells
- 17
- Bought
- $942K
- Sold
- $31.4M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 1 May 2015
- Last trade
- 1 Aug 2026
- Last filed
- 3 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Aug 2026filed 3 Aug 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 1 Aug 2026filed 3 Aug 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 11 Jun 2026filed 11 Jun 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 11 Jun 2026filed 11 Jun 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 1 Jan 2026filed 2 Jan 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,888 at $0.00 | filing |
| 1 Jan 2026filed 2 Jan 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,888 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 1 Jan 2025filed 2 Jan 2025 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,485 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 1 Jan 2024filed 2 Jan 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,879 at $0.00 | filing |
| 22 Jun 2023filed 26 Jun 2023 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 14 Jun 2023filed 15 Jun 2023 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 11 Jan 2023filed 11 Jan 2023 | Imago BioSciencesoption or derivative | SEC FORM 4 Code D | —23,809 | filing |
| 11 Jan 2023filed 11 Jan 2023 | Imago BioSciencesoption or derivative | SEC FORM 4 Code D | —11,904 | filing |
| 21 Jun 2022filed 23 Jun 2022 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,200 at $0.00 | filing |
| 1 Jun 2022filed 3 Jun 2022 | Imago BioSciencesoption or derivative | SEC FORM 4 Code A | —11,904 at $0.00 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Laurie Keating; 3 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.